Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Majithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL [abstract FR-OR18]. J Am Soc Nephrol. 2020;31(suppl):21. https://www.asn-online.org/education/kidneyweek/archives/KW20Abstracts.pdf
European Association for the Study of Diabetes
Bhatt DL, Brinton E, Miller M, et al. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract 627]. Presented at the European Association for the Study of Diabetes meeting, September 21-25, 2020 (virtual). Diabetologia. 2020;63(1 suppl):303. https://upload.easd.org/download/EASD2020/Abstract%20Volume%2056th%20EASD%20Annual%20Meeting.pdf
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
Sherratt SCR, Mason RP. Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure. Presented at the European Atherosclerosis Society meeting, October 4-7, 2020 (virtual).
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups.
European Society of Cardiology – Freely accessible
Bhatt DL, Miller M, Steg PG, et al. REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups. Presented at the European Society of Cardiology meeting, August 29-September 2, 2020 (virtual).
REDUCE-IT: Accumulation of data across prespecified interim analyses to final results.
Olshansky B, Bhatt DL, Miller M, et al. REDUCE-IT: Accumulation of data across prespecified interim analyses to final results. Presented at the European Society of Cardiology meeting, August 29-September 2, 2020 (virtual).
Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI.
Transcatheter Cardiovascular Therapeutics Scientific Symposium
Peterson BE, Bhatt DL, Steg PG, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI. Presented at the Transcatheter Cardiovascular Therapeutics Scientific Symposium, October 14-18, 2020 (virtual).

Amarin Corporation